Table 4.
Results of gene-based tests. Results from gene-based tests with MAGMA representing the joint effects of common SNPs within the named gene (NB: for PC1 no genome-wide significant gene-based results were observed)
| Outcome | Gene | Chr | Start | End | Nsnps | Z | P |
|---|---|---|---|---|---|---|---|
| Genome-wide significant genes | |||||||
| Aβ Pathology (PC2) | APOE | 19 | 45409011 | 45412650 | 6 | 7.91 | 1.3E−15 |
| Injury/Inflammation (PC3) | TMEM106B | 7 | 12250867 | 12282993 | 182 | 5.75 | 4.6E−09 |
| Non-AD Inflammation (PC4) | CHI3L1 | 1 | 203148059 | 203155877 | 28 | 4.53 | 2.9E−06 |
| Non-AD Synaptic Functioning (PC5) | GRIN2D | 19 | 48898132 | 48948188 | 110 | 4.63 | 1.8E−06 |
| Comparison with rare-variant hits | |||||||
| Injury/Inflammation | IFFO1 | 12 | 6647541 | 6665239 | 46 | 0.50 | 0.307 |
| Injury/Inflammation | DTNB | 2 | 25600067 | 25896503 | 385 | −1.11 | 0.867 |
| Injury/Inflammation | NLRC3 | - | - | - | - | - | - |
| Injury/Inflammation | SLC22A10 | 11 | 62905339 | 63137190 | 564 | −1.79 | 0.963 |
| Non-AD Synaptic Functioning | GABBR2 | 9 | 101050391 | 101471479 | 1445 | 1.41 | 0.079 |
| Non-AD Synaptic Functioning | CASZ1 | 1 | 10696661 | 10856707 | 387 | 0.32 | 0.374 |
Chr chromosome, Start/End SNPs between start and end were considered, Nsnps number of SNPs included in test, Z Z test statistic, p p-value